Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00QIJ
|
|||
| Former ID |
DPR000122
|
|||
| Drug Name |
Huntingtin gene antisense
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Preclinical | [1] | |
| Therapeutic Class |
Antisense
|
|||
| Company |
Alnylam Pharmaceuticals & Medtronic, Inc.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Huntingtin messenger RNA (HTT mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. | |||
| REF 2 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.